Across TCGA cell cohorts, RBM43 mutation is significantly associated with the drug of many other genes, with 34 significant associations in total. LARGE_INTESTINE shows the largest number of these associations.

The most reproducible RBM43-associated genes across cancer lineages are Methotrexate, FY012, and Doxorubicin. Each is linked with RBM43 in more than 1 cancer types. Because this analysis shows association rather than direction, both RBM43-to-partner and partner-to-RBM43 results are reported.

Each partner links to its own Q-omics profile.

mutation associated genes by consensus

Ranked by combined sampling and lineage consensus. X-score (RBM43→partner) and Y-score (partner→RBM43) are standardized regression coefficients; both directions are reported because the association is undirected. p-values are from the association test.

Lineage	Partner gene	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
LARGE_INTESTINE	Methotrexate →	+1.097	+2.807	.004	.035	3	1
LARGE_INTESTINE	FY012 →	+0.507	+2.710	.013	.027	3	1
LARGE_INTESTINE	Doxorubicin →	+0.562	+2.649	.037	.046	3	1
LARGE_INTESTINE	JAK3_7406 →	+0.671	+2.649	<.001	.046	3	1
LARGE_INTESTINE	Pevonedistat →	+0.908	+2.871	.004	.021	3	1
LARGE_INTESTINE	720427 →	+0.307	+2.871	.013	.021	3	1

Each partner links to its Q-omics profile. Showing the 6 strongest of 34 associations by consensus.

Exploration

RBM43 survival (RNA) · tumor vs normal (RNA) · all RBM43 data types